Cargando…

Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease characterized by joint and entheses involvement. This condition is often associated with an increased prevalence of obesity, encompassing more than one-third of all patients. Given the presence of metabolic disorders, it becomes cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grygiel-Górniak, Bogna, Skoczek, Weronika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532042/
https://www.ncbi.nlm.nih.gov/pubmed/37762754
http://dx.doi.org/10.3390/jcm12185814
_version_ 1785111862494363648
author Grygiel-Górniak, Bogna
Skoczek, Weronika
author_facet Grygiel-Górniak, Bogna
Skoczek, Weronika
author_sort Grygiel-Górniak, Bogna
collection PubMed
description Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease characterized by joint and entheses involvement. This condition is often associated with an increased prevalence of obesity, encompassing more than one-third of all patients. Given the presence of metabolic disorders, it becomes crucial to enhance clinical oversight of metabolic parameters. An early diagnosis of glucose irregularities in PsA allows for the assessment of an effective treatment strategy. The approach proves valuable in preventing the development of insulin resistance (IR) or diabetes mellitus type 2 (DMt2). Similar pathways characterize the pathomechanism of PsA and DMt2, offering an innovative perspective on treatment management. The cytokines and adipokines synthesized in the course of PsA significantly impact the development process of IR and DMt2 in different mechanisms of action. Conversely, glucose disorders influence the activity of PsA and therapy outcomes. Given the chronic inflammatory background shared by PsA, obesity, and DMt2, it is evident that inadequate management of any of the mentioned conditions can exacerbate the others. Thus, when PsA coincides with DMt2, a comprehensive multidimensional approach is necessary. This includes an effective immunosuppressive regimen complemented by appropriate anti-diabetic and insulin therapies. Moreover, often overlooked recommendations concerning overall well-being and lifestyle adjustments hold significance. This manuscript explores the connections and the relationship between the molecular background of PsA and glucose disorders. It provides a detailed exposition of specific therapeutic approaches for both conditions.
format Online
Article
Text
id pubmed-10532042
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105320422023-09-28 Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis Grygiel-Górniak, Bogna Skoczek, Weronika J Clin Med Review Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease characterized by joint and entheses involvement. This condition is often associated with an increased prevalence of obesity, encompassing more than one-third of all patients. Given the presence of metabolic disorders, it becomes crucial to enhance clinical oversight of metabolic parameters. An early diagnosis of glucose irregularities in PsA allows for the assessment of an effective treatment strategy. The approach proves valuable in preventing the development of insulin resistance (IR) or diabetes mellitus type 2 (DMt2). Similar pathways characterize the pathomechanism of PsA and DMt2, offering an innovative perspective on treatment management. The cytokines and adipokines synthesized in the course of PsA significantly impact the development process of IR and DMt2 in different mechanisms of action. Conversely, glucose disorders influence the activity of PsA and therapy outcomes. Given the chronic inflammatory background shared by PsA, obesity, and DMt2, it is evident that inadequate management of any of the mentioned conditions can exacerbate the others. Thus, when PsA coincides with DMt2, a comprehensive multidimensional approach is necessary. This includes an effective immunosuppressive regimen complemented by appropriate anti-diabetic and insulin therapies. Moreover, often overlooked recommendations concerning overall well-being and lifestyle adjustments hold significance. This manuscript explores the connections and the relationship between the molecular background of PsA and glucose disorders. It provides a detailed exposition of specific therapeutic approaches for both conditions. MDPI 2023-09-07 /pmc/articles/PMC10532042/ /pubmed/37762754 http://dx.doi.org/10.3390/jcm12185814 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Grygiel-Górniak, Bogna
Skoczek, Weronika
Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title_full Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title_fullStr Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title_full_unstemmed Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title_short Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
title_sort molecular background and clinical implications of glucose disorders in patients with psoriatic arthritis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532042/
https://www.ncbi.nlm.nih.gov/pubmed/37762754
http://dx.doi.org/10.3390/jcm12185814
work_keys_str_mv AT grygielgorniakbogna molecularbackgroundandclinicalimplicationsofglucosedisordersinpatientswithpsoriaticarthritis
AT skoczekweronika molecularbackgroundandclinicalimplicationsofglucosedisordersinpatientswithpsoriaticarthritis